Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsVentura County Daklinza Prior Auth | OpenPayer
    Ask Trek AI about this page
    RetiredVentura County Health Care PlanPolicy N/A

    Daklinza (daclatasvir) Prior Authorization

    Customize your policy alerts

    Sign up for all venturacountyhealthcareplan policy alerts

    Know when venturacountyhealthcareplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs exception-review coverage of Daklinza for adults with chronic hepatitis C virus infection, including selected post-liver-transplant cases. It specifies prescriber, combination-therapy, fibrosis, cirrhosis, genotype, and treatment-duration requirements.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyDaklinza (daclatasvir) Prior Authorization
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateJul 24, 2018
    Last ReviewJan 22, 2019
    Next Review DateN/A
    Key ActionSubmit documentation of patient age, HCV genotype, fibrosis score when required, cirrhosis and Child-Pugh status when applicable, transplant history, specialist involvement, and planned combination regimen.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 weeksStandard authorized treatment duration
    24 weeksMaximum authorization for completion of therapy
    18 yearsMinimum patient age
    1, 2, 3Genotypes addressed by covered criteria

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ≥2Required fibrosis threshold
    Exception review onlyCoverage status

    Covered Indications

    Chronic HCV genotype 1

    Approve Daklinza for 12 weeks when ALL of the following are met.

    Genotype 1 chronic HCV: Patient has chronic HCV genotype 1 infection.

    Required criteria

    • Age: Patient is at least 18 years old.≥18 years
    • Specialist involvement: Daklinza is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician.
    • Combination therapy: Daklinza is used in combination with Sovaldi (sofosbuvir tablets).
    • Fibrosis: Patient has a fibrosis score of at least 2.≥2
    • Cirrhosis status

      • No cirrhosis: Patient does not have cirrhosis.
      • Compensated cirrhosis: Patient has compensated cirrhosis (Child-Pugh A).Child-Pugh A
      • Decompensated cirrhosis: Patient has decompensated cirrhosis (Child-Pugh B or C) and Daklinza is prescribed with ribavirin.Child-Pugh B or C

    Chronic HCV genotype 3

    Approve Daklinza for 12 weeks when ALL of the following are met.

    Genotype 3 chronic HCV: Patient has chronic HCV genotype 3 infection.

    Required criteria

    • Age: Patient is at least 18 years old.≥18 years
    • Specialist involvement: Daklinza is prescribed by or in consultation with a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician.
    • Combination therapy: Daklinza is used in combination with Sovaldi (sofosbuvir tablets).

    Recurrent HCV after liver transplantation, genotype 1 or 3

    Approve Daklinza for 12 weeks when ALL of the following are met.

    Recurrent post-transplant HCV genotypes 1 or 3: Patient has genotype 1 or 3 recurrent HCV after liver transplantation.Genotype 1 or 3

    Required criteria

    • Age: Patient is at least 18 years old.≥18 years
    • Specialist involvement: Daklinza is prescribed by or in consultation with a prescriber affiliated with a liver transplant center, a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician.

    Recurrent HCV after liver transplantation, genotype 2

    Approve Daklinza for 12 weeks when ALL of the following are met.

    Recurrent post-transplant HCV genotype 2: Patient has genotype 2 recurrent HCV after liver transplantation.Genotype 2

    Required criteria

    • Age: Patient is at least 18 years old.≥18 years
    • Specialist involvement: Daklinza is prescribed by or in consultation with a prescriber affiliated with a liver transplant center, a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician.

    Continuation therapy

    Approve continuation when ALL of the following are met.

    Existing eligible therapy: Patient has already started Daklinza for an indication or condition addressed as approvable in the Recommended Authorization Criteria or Other Uses with Supportive Evidence section.
    Completion of course: Authorization is limited to the remaining portion of the eligible treatment course and does not exceed 24 weeks of total therapy.≤24 weeks total

    For example, a patient eligible for 12 weeks who has received 3 weeks may receive 9 additional weeks.

    Coverage requires Daklinza to be used in an approved combination regimen. Combination with direct-acting antivirals other than Sovaldi or ribavirin is not covered, and Daklinza monotherapy is not approved. Coverage is also not approved when the patient’s life expectancy is under 12 months because of non-liver-related comorbidities.

    Clinical Coding and Thresholds

    Fibrosis score
    Required thresholdFibrosis score ≥ 2

    Authorization and Review Requirements

    Prior Authorization

    Formulary Exclusion — Exception Review Required

    Daklinza is a formulary exclusion and is available for exception review only. Coverage is recommended only when the applicable authorization criteria are satisfied.

    • Exception review is required before coverage can be authorized.
    • Daklinza is indicated with Sovaldi, with or without ribavirin, for chronic HCV genotype 1 or 3; applicable supportive-evidence criteria also include certain post-liver-transplant cases.
    Prior Authorization

    Authorization Duration

    Initial authorization is generally for 12 weeks when the applicable criteria are met. Patients already receiving Daklinza may receive only the remaining amount needed to complete an approved course, and total authorization must not exceed 24 weeks.

    • For a 12-week course, authorize only the remaining weeks; for example, 9 weeks if 3 weeks have already been completed.
    • Completion authorization may be granted for an indication or condition addressed as an approval under the FDA-approved indications or other uses with supportive evidence.

    Therapeutic Background

    Daklinza (daclatasvir) is an HCV NS5A inhibitor used with Sovaldi (sofosbuvir), with ribavirin added when required by the patient’s genotype, cirrhosis status, or post-transplant status. The policy addresses treatment of chronic HCV genotypes 1 and 3, recurrent HCV genotypes 1, 2, and 3 after liver transplantation, and completion of an eligible Daklinza treatment course.

    Clinical Definitions

    Cirrhosis classification
    Compensated cirrhosisChild-Pugh A
    Decompensated cirrhosisChild-Pugh B or C

    Initial Therapy

    Genotype 1 initial therapy

    Approve for 12 weeks when all genotype 1 criteria are satisfied.

    Genotype 1 regimen: Adult patient with chronic HCV genotype 1, fibrosis score ≥2, specialist prescribing or consultation, and Daklinza plus Sovaldi therapy; cirrhosis status determines whether ribavirin is required.12 weeks

    Decompensated cirrhosis requires ribavirin.

    Genotype 3 initial therapy

    Approve for 12 weeks when all genotype 3 criteria are satisfied.

    Genotype 3 regimen: Adult patient with chronic HCV genotype 3, fibrosis score ≥2, specialist prescribing or consultation, and Daklinza plus Sovaldi therapy; cirrhosis requires ribavirin.12 weeks

    Cirrhosis includes compensated Child-Pugh A and decompensated Child-Pugh B or C.

    Continuation and Completion of Therapy

    Continuation or completion of therapy

    Approve to complete an eligible course, subject to a maximum of 24 weeks of total therapy.

    Started eligible therapy: Patient has been started on Daklinza for an indication or condition approved under this policy.
    Remaining course only: Authorize only the number of weeks remaining in the eligible course; total Daklinza therapy must not exceed 24 weeks.≤24 weeks total

    Authorized Quantity Limits

    Daklinza quantity limit
    Standard authorized quantity12 weeks per course
    Daklinza completion limit
    Maximum completion-of-therapy quantity24 weeks per course
    Policy Summary
    PayerVentura County Health Care Plan
    PolicyDaklinza (daclatasvir) Prior Authorization
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateJul 24, 2018
    Last ReviewJan 22, 2019
    Next Review DateN/A
    Key ActionSubmit documentation of patient age, HCV genotype, fibrosis score when required, cirrhosis and Child-Pugh status when applicable, transplant history, specialist involvement, and planned combination regimen.
    SourceLink
    On This Page
    Covered IndicationsClinical Coding and ThresholdsAuthorization and Review RequirementsTherapeutic BackgroundClinical DefinitionsInitial TherapyContinuation and Completion of TherapyAuthorized Quantity Limits
  1. Fibrosis: Patient has a fibrosis score of at least 2.≥2
  2. Cirrhosis status

    • No cirrhosis: Patient does not have cirrhosis.
    • Cirrhosis with ribavirin: Patient has compensated or decompensated cirrhosis and Daklinza and Sovaldi are prescribed in combination with ribavirin.Child-Pugh A, B, or C
  3. Combination therapy: Daklinza is prescribed in combination with Sovaldi and ribavirin.
    Combination therapy:
    Daklinza is prescribed in combination with Sovaldi and ribavirin.
  4. Authorization should not exceed 24 weeks of therapy.
  5. Documentation Required

    Clinical Documentation Required

    The request must document the patient’s eligibility, diagnosis, treatment plan, and relevant disease severity. Documentation must support the applicable indication and prescribing requirements before authorization is approved.

    • Patient is at least 18 years of age.
    • HCV genotype and applicable indication are documented: chronic genotype 1 or 3, or recurrent HCV after liver transplantation (including genotype 2 under supportive-evidence criteria).
    • Prescriber is a gastroenterologist, hepatologist, infectious diseases physician, or liver transplant physician; post-transplant prescribing may also be by or in consultation with a physician affiliated with a liver transplant center.
    • For chronic genotype 1 or 3, Daklinza is prescribed with Sovaldi and the patient has a fibrosis score of ≥ 2.
    • Cirrhosis status and Child-Pugh classification are documented: no cirrhosis, compensated cirrhosis (Child-Pugh A), or decompensated cirrhosis (Child-Pugh B or C).
    • When required, ribavirin is included for decompensated cirrhosis, cirrhosis in genotype 3, and recurrent post-liver-transplant HCV.
    • For post-liver-transplant requests, documentation confirms recurrent HCV, genotype, transplant history, and the required Sovaldi plus ribavirin regimen.
    Denial Risk

    Noncovered Uses

    Daklinza is not approved for uses excluded by the policy. Requests for these uses are not covered, even when Daklinza is otherwise clinically appropriate.

    • Monotherapy with Daklinza.
    • Combination with direct-acting antivirals (DAAs) other than Sovaldi or ribavirin.
    • Retreatment in patients who previously received Daklinza.
    • Pediatric use in patients younger than 18 years.
    • Use when life expectancy is less than 12 months because of non-liver-related comorbidities.
    Denial Risk

    Failure to Meet Indication Criteria

    Authorization will be denied when the request does not meet all required criteria for the applicable indication or when required clinical or prescribing documentation is absent. The requested regimen, diagnosis, disease severity, and treatment history must support an approved use.

    • Patient is younger than 18 years of age.
    • Daklinza is not prescribed by or in consultation with a qualified specialist, including an appropriately affiliated liver-transplant prescriber when required.
    • For chronic genotype 1 or 3, the request lacks Sovaldi coadministration, the required fibrosis score of ≥ 2, or the applicable cirrhosis/Child-Pugh criteria.
    • Required ribavirin is omitted for decompensated cirrhosis, cirrhosis in genotype 3, or recurrent post-liver-transplant HCV.
    • Post-liver-transplant recurrence, genotype, transplant history, or required Sovaldi plus ribavirin therapy is not documented.
    • The request is for an indication not addressed as an approval under the FDA-approved indications or other uses with supportive evidence, or the request otherwise fails the applicable criteria.

    Recurrent post-liver-transplant therapy

    Approve for 12 weeks when all post-transplant criteria are satisfied.

    Post-transplant regimen: Adult patient with recurrent HCV after liver transplantation, genotype 1, 2, or 3, prescribed Daklinza with Sovaldi and ribavirin by or in consultation with an eligible specialist or liver-transplant-center-affiliated prescriber.12 weeks